<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01445730</url>
  </required_header>
  <id_info>
    <org_study_id>T1010K0029</org_study_id>
    <nct_id>NCT01445730</nct_id>
  </id_info>
  <brief_title>Fructose Consumption and Metabolic Dysregulation</brief_title>
  <official_title>Fructose Consumption Aggravates Dysregulation of Postprandial Lipid Metabolism in Obese Hypertriglyceridemic Men With High Cardiometabolic Risk Profile and Associates With Liver Fat Deposition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marja-Riitta Taskinen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Naples</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High fructose intake is increasingly recognized as causative in development of prediabetes,
      metabolic syndrome and cardiovascular disease (CVD). The mechanisms underlying
      fructose-induced metabolic disturbances are unclear but are beginning to be unraveled. In
      contrast to metabolism of glucose, the breakdown of fructose leads to the generation of
      metabolites that stimulate hepatic de novo lipogenesis (DNL) and increased levels of both
      fasting and postprandial triglycerides. The key lipogenic transcription factor seems to be
      activated by fructose independently of insulin. However, it is still controversial whether
      fructose consumption increases DNL in man to the extent that it induces metabolic
      disturbances. Animal studies have shown that also the adipose tissue is responsive to
      fructose feeding fructose, and that high fructose-feeding induces insulin resistance and
      inflammation in the adipose tissue. The role of intestinal insulin resistance in
      fructose-induced dysmetabolism has not been studied in detail. The critical question is
      whether the metabolic disturbances are induced by calorie excess or by fructose per se.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed description: Study subjects will participate to studies 1-4 before and 3 m after
      fructose diet:

        1. An oral fat load or a kinetic study with stable isotopes combined with an oral fat load.

        2. Determination of liver, subcutaneous and intra-abdominal fat. (Proton magnetic resonance
           spectroscopy )

        3. Lipolytic enzymes, advanced lipid analysis, fat biopsies and genetic studies and gut
           microbiota profiling

        4. Oral glucose tolerance test and analysis of incretins and inflammatory biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Triglyceride (TG) area under curve (AUC)</measure>
    <time_frame>3 months</time_frame>
    <description>Before vs. after fructose challenge: Postprandial plasma TG summary measure expressed as AUC (baseline to 8hours) after oral fat.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Very low density lipoprotein 1 (VLDL1) apolipoprotein B-100 (ApoB-100) kinetics</measure>
    <time_frame>3 months</time_frame>
    <description>Before vs. after fructose challenge: VLDL1 ApoB-100 secretion rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VLDL1 ApoB-100 kinetics</measure>
    <time_frame>3 months</time_frame>
    <description>VLDL1 ApoB-100 catabolic rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic parameters</measure>
    <time_frame>3 months</time_frame>
    <description>Before vs. after fructose challenge: Postprandial lipids and apolipoproteins (8hours) after oral fat and/or non-steady state kinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic parameters</measure>
    <time_frame>3 months</time_frame>
    <description>Before vs. after fructose challenge: Hepatic DNL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic parameters</measure>
    <time_frame>3 months</time_frame>
    <description>Before vs. after fructose challenge: Plasma inflammatory markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic parameters</measure>
    <time_frame>3 months</time_frame>
    <description>Before vs. after fructose challenge: Incretin response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic parameters</measure>
    <time_frame>3 months</time_frame>
    <description>Before vs. after fructose challenge: Plasma and adipose tissue lipidomics /genetics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic parameters</measure>
    <time_frame>3 months</time_frame>
    <description>Before vs. after fructose challenge: Gut microbiota profiling.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Central Obesity</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Hypercaloric fructose diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1. TG ≤1.7 mmo/l 2. TG &gt; 1.7 mmol/l</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isocaloric fructose diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3. TG ≤1.7 mmo/l 4. TG &gt; 1.7 mmol/l</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fructose</intervention_name>
    <description>fructose drink 75 g/day per day while consuming a self-selected ad libitum diet</description>
    <arm_group_label>Hypercaloric fructose diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fructose</intervention_name>
    <description>3 month fructose diet 75 g/day while consuming isocaloric diet</description>
    <arm_group_label>Isocaloric fructose diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index 27-40

          -  Waist &gt; 96 cm

          -  Age 20-60 years

          -  Male

        Exclusion Criteria:

          -  Smoking

          -  Active health problems

          -  Contraindications to MRI scanning

          -  Bleeding tendency

          -  Abnormal liver or renal function tests

          -  Type 2 diabetes

          -  Evidence of metabolic or viral liver disease

          -  Alcohol intake &gt; 21 units per week

          -  Chronic medication except ones needed for stable hypertension
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marja-Riitta Taskinen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, Biomedicum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Université Laval</name>
      <address>
        <city>Québec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital, Biomedicum</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Naples, Federico II, and Faculty of Medicine</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Academy at University of Gothenburg and Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>Italy</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2011</study_first_submitted>
  <study_first_submitted_qc>September 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2011</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Marja-Riitta Taskinen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>fructose</keyword>
  <keyword>hypertriglyceridemia</keyword>
  <keyword>postprandial lipids</keyword>
  <keyword>de novo lipogenesis</keyword>
  <keyword>stable isotopes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

